cancer

An artificial intelligence (AI) algorithm is capable of estimating a woman's risk of developing breast cancer in the next four years, according to a study published in The Lancet Digital Health. The tool identified women at high risk of developing breast cancer, and nearly one in ten of those who scored in the top 2% according to the algorithm were diagnosed within four years, despite having been discharged from hospital. The tool used mammograms from nearly 400,000 women and was then tested with data from nearly 96,000 women in Australia. The results were confirmed in a Swedish population of more than 4,500 women.

A study published in The Lancet Oncology shows that age-adjusted breast cancer mortality has declined from 1990 to 2023, even though the number of cases has increased. In Spain, the mortality rate for this disease fell by almost 42% during this period, reflecting the success of screening, diagnosis and treatment in high-income countries, according to the article's data. Although incidence and mortality rates will remain stable, the authors predict that population growth and ageing will increase the number of breast cancer cases and deaths between now and 2050.

Cancer patients receiving a type of immunotherapy known as Immune Checkpoint Inhibitor (ICI) have a higher risk of serious adverse events, such as aortic aneurysm rupture, interstitial lung disease, myositis and liver failure, according to a study published in PNAS. "Establishing formal contraindications for ICI users seems warranted," concludes the analysis, based on more than 290,000 cases from pharmacovigilance databases of the US Food and Drug Administration and the World Health Organisation.

Although CAR-T cells have been effective against certain blood cancers, they have not worked well in solid tumors due to the lack of a common target on the surface of the cells. A study published today in the journal Science has developed ultra-sensitive CAR-T cells capable of detecting even very low levels of the CD70 protein, a promising target. The researchers succeeded in eradicating kidney, ovarian, and pancreatic tumors in preclinical models.

The p53 gene, known as the ‘guardian of the genome’, is a tumor suppressor gene that is mutated in more than half of all solid tumors in humans, affecting the function of the protein it encodes. However, there are no approved treatments capable of reactivating its function. A US team has tested a new drug in a phase 1 clinical trial that is capable of performing this function against a specific mutation, present in approximately 1% of solid tumors. After being administered to 77 people with different types of advanced or metastatic tumors, 20% showed a full or partial response, and the most common adverse effects were nausea or vomiting, according to a report published in NEJM.  

Counties in the United States closest to operating nuclear power plants have higher cancer mortality rates than those further away, according to a new study led by the Harvard T.H. Chan School of Public Health, published in Nature Communications. Using data from 2000 to 2018, they assessed spatial patterns of cancer mortality in relation to proximity to nuclear facilities, taking into account socioeconomic, environmental, and health factors. Cancer mortality was higher in both men and women, with the strongest associations among men aged 65 to 74 and women aged 55 to 64. The findings do not imply causality.

Although cancer is a common cause of death in domestic cats, little is known about the range of genes affected and how they compare with the oncogenome in humans. A study published in Science sequenced cancer-related genes in 493 samples from 13 different types of feline cancer to obtain a clearer picture of the feline oncogenome. The genes were also compared with known cancer-associated mutations in humans.

A team in China has studied the ability of a test to detect the human papillomavirus (HPV)—responsible for the vast majority of cervical cancers—in menstrual blood from more than 3,000 women. The results indicate that the test is comparable to current screening performed in medical offices. According to the researchers, “Using menstrual blood for HPV testing is practical and non-invasive, allowing women to collect samples at home and thus potentially offering a practical way to expand access to screening.” The study is published in The BMJ. 

In 2022, approximately four out of every 10 new cancer cases worldwide were due to modifiable risk factors, primarily tobacco or alcohol consumption and infections, including those caused by the human papillomavirus or H. pylori bacteria. These are some of the conclusions of a global study led by the World Health Organisation (WHO) and its International Agency for Research on Cancer (IARC), published in Nature Medicine. In Spain, 41.8% of cancer cases in men are attributed to modifiable external factors, compared to 26.1% in women, with smoking remaining the main factor (28.5% and 9.9%, respectively). The analysis is based on data from 185 countries.

A phase 3 clinical trial conducted in China tested 210 patients with advanced non-small cell lung cancer—the most common type—to see whether the time of day when immunotherapy and chemotherapy were administered influenced their effectiveness. The data indicate that, on average, those who received therapy after 3 p.m. did not see their cancer worsen for 5.4 months. In contrast, those who received it before that time did not see their cancer worsen for an average of 11.7 months, almost twice as long. Overall, response rates were 56.2% and 69.5%, respectively. The results, published in Nature Medicine, suggest that scheduling therapy early in the day may offer a simple and cost-free way to improve treatment efficacy.